Integra LifeSciences Holdings Corporation (NASDAQ:IART) – Equities researchers at Oppenheimer Holdings lowered their FY2019 earnings per share estimates for Integra LifeSciences Holdings Corporation in a research report issued on Friday. Oppenheimer Holdings analyst S. Lichtman now anticipates that the life sciences company will post earnings of $2.59 per share for the year, down from their prior estimate of $2.74. Oppenheimer Holdings has a “Buy” rating on the stock.

Several other brokerages have also weighed in on IART. BidaskClub lowered shares of Integra LifeSciences Holdings Corporation from a “buy” rating to a “hold” rating in a research report on Monday, July 24th. Cantor Fitzgerald restated an “overweight” rating and set a $65.00 target price on shares of Integra LifeSciences Holdings Corporation in a research report on Monday, July 10th. Barclays PLC restated an “equal weight” rating and set a $53.00 target price (up from $47.00) on shares of Integra LifeSciences Holdings Corporation in a research report on Tuesday, September 12th. Jefferies Group LLC restated a “buy” rating on shares of Integra LifeSciences Holdings Corporation in a research report on Sunday, September 10th. Finally, Zacks Investment Research lowered shares of Integra LifeSciences Holdings Corporation from a “buy” rating to a “hold” rating in a research report on Monday, October 9th. Seven analysts have rated the stock with a hold rating and seven have assigned a buy rating to the company’s stock. The stock currently has a consensus rating of “Buy” and an average target price of $53.91.

WARNING: “Integra LifeSciences Holdings Corporation (IART) to Post FY2019 Earnings of $2.59 Per Share, Oppenheimer Holdings Forecasts” was first posted by American Banking News and is owned by of American Banking News. If you are viewing this article on another publication, it was illegally stolen and republished in violation of US and international copyright and trademark laws. The original version of this article can be viewed at https://www.americanbankingnews.com/2017/10/30/integra-lifesciences-holdings-corporation-iart-to-post-fy2019-earnings-of-2-59-per-share-oppenheimer-holdings-forecasts.html.

Shares of Integra LifeSciences Holdings Corporation (IART) traded down 0.97% on Monday, reaching $45.87. 529,069 shares of the company were exchanged. The company has a market capitalization of $3.58 billion, a P/E ratio of 55.94 and a beta of 0.72. The stock has a 50 day moving average of $50.38 and a 200-day moving average of $49.99. Integra LifeSciences Holdings Corporation has a 52-week low of $37.71 and a 52-week high of $56.42.

Integra LifeSciences Holdings Corporation (NASDAQ:IART) last issued its quarterly earnings results on Thursday, October 26th. The life sciences company reported $0.45 earnings per share for the quarter, missing the Zacks’ consensus estimate of $0.47 by ($0.02). The company had revenue of $278.83 million during the quarter, compared to analysts’ expectations of $286.00 million. Integra LifeSciences Holdings Corporation had a net margin of 4.52% and a return on equity of 16.35%. The company’s quarterly revenue was up 11.4% compared to the same quarter last year. During the same period in the prior year, the business posted $0.93 earnings per share.

In other news, Director Donald E. Morel, Jr. acquired 10,000 shares of Integra LifeSciences Holdings Corporation stock in a transaction that occurred on Friday, August 4th. The shares were acquired at an average price of $49.25 per share, with a total value of $492,500.00. Following the completion of the purchase, the director now owns 29,612 shares of the company’s stock, valued at approximately $1,458,391. The transaction was disclosed in a filing with the SEC, which can be accessed through this link. Also, Director Barbara B. Hill acquired 5,050 shares of Integra LifeSciences Holdings Corporation stock in a transaction that occurred on Tuesday, August 1st. The shares were purchased at an average cost of $49.33 per share, for a total transaction of $249,116.50. Following the purchase, the director now directly owns 44,772 shares of the company’s stock, valued at approximately $2,208,602.76. The disclosure for this purchase can be found here. Insiders bought 17,550 shares of company stock worth $864,842 over the last quarter. Company insiders own 21.50% of the company’s stock.

Several institutional investors and hedge funds have recently made changes to their positions in the stock. FMR LLC lifted its stake in shares of Integra LifeSciences Holdings Corporation by 6.2% during the second quarter. FMR LLC now owns 8,084,562 shares of the life sciences company’s stock valued at $440,690,000 after buying an additional 468,678 shares during the period. BlackRock Inc. lifted its stake in shares of Integra LifeSciences Holdings Corporation by 307,726.8% during the first quarter. BlackRock Inc. now owns 7,455,564 shares of the life sciences company’s stock valued at $314,104,000 after buying an additional 7,453,142 shares during the period. Vanguard Group Inc. lifted its stake in shares of Integra LifeSciences Holdings Corporation by 116.7% during the first quarter. Vanguard Group Inc. now owns 5,656,048 shares of the life sciences company’s stock valued at $238,289,000 after buying an additional 3,046,488 shares during the period. Capital Research Global Investors lifted its stake in shares of Integra LifeSciences Holdings Corporation by 227.0% during the second quarter. Capital Research Global Investors now owns 3,897,288 shares of the life sciences company’s stock valued at $212,441,000 after buying an additional 2,705,488 shares during the period. Finally, Janus Henderson Group PLC purchased a new position in shares of Integra LifeSciences Holdings Corporation during the second quarter valued at approximately $112,068,000. 84.88% of the stock is currently owned by institutional investors and hedge funds.

About Integra LifeSciences Holdings Corporation

Integra LifeSciences Holdings Corporation is a medical technology company. The Company focuses on the development, manufacturing, and marketing of surgical implants and medical instruments. Its segments include Specialty Surgical Solutions, which offers specialty surgical instrumentation for a range of specialties, including product portfolio used in the neurosurgery operating suite and critical care unit, and Orthopedics and Tissue Technologies, which includes differentiated soft tissue repair and tissue regeneration products, and small bone fixation and joint replacement solutions.

Earnings History and Estimates for Integra LifeSciences Holdings Corporation (NASDAQ:IART)

Receive News & Ratings for Integra LifeSciences Holdings Corporation Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Integra LifeSciences Holdings Corporation and related companies with MarketBeat.com's FREE daily email newsletter.